Analysis
Attovia Therapeutics set terms for its Nasdaq initial public offering, planning to sell 12.5 million shares at a proposed range of $15 to $17, targeting roughly $200 million and up to $212.5 million at the top of the range. The Goldman-backed biotech will list under the ticker ATTO.
The company's lead program, ATTO-1310, targets IL-31 and has completed Phase 1 dosing in both healthy volunteers and patients with chronic pruritus and atopic dermatitis -- chronic itch and eczema conditions affecting a large patient population that remains underserved by current treatment options. A second candidate, ATTO-2306, a bispecific molecule targeting both IL-13 and IL-31 for atopic dermatitis and related skin conditions, is currently in IND-enabling studies ahead of a planned Phase 1 trial in the first half of 2027.
“At the midpoint of its proposed range, Attovia would command a fully diluted market value of roughly $649 million heading into trading.”
At the midpoint of its proposed range, Attovia would command a fully diluted market value of roughly $649 million heading into trading. The offering continues a genuinely strong run for clinical-stage biotech IPOs this month: Apnimed priced its own offering at the top of its range just a day earlier, and Scribe Therapeutics popped nearly 44% on its first trading day after pricing on July 23.
For biotech-focused investors, Attovia's terms reinforce that the current IPO window is rewarding single-modality, clinically-de-risked immune-disease programs with genuine unmet-need stories, even as broader consumer-tech and generalist listings have had a far more mixed reception this same week. The bear case remains constant across every clinical-stage biotech IPO: approval risk doesn't disappear at listing, and a disappointing trial readout would erase today's IPO premium regardless of how strong the offering itself performs. What to watch: Attovia's actual pricing and first-day trading performance relative to Apnimed and Scribe, and progress toward ATTO-2306's Phase 1 start.
